Covid-19: Oxford University vaccine shows 70% protection

0

The coronavirus vaccine developed by the University of Oxford stops 70% of people developing Covid symptoms, a large-scale trial shows.

It will be seen as both a triumph and a disappointment after vaccines by Pfizer and Moderna showed 95% protection.

However, the Oxford jab is far cheaper, and is easier to store and get to every corner of the world than the other two.

So it will still play a significant role in tackling the pandemic, if it is approved by regulators.

There is also intriguing data that suggests perfecting the dose could increase protection up to 90%.

The UK government has pre-ordered 100 million doses of the Oxford vaccine, enough to immunise 50 million people.

Prime Minister Boris Johnson said: “Incredibly exciting news the Oxford vaccine has proved so effective in trials.

“There are still further safety checks ahead, but these are fantastic results.”

The Oxford researchers have developed the vaccine in around 10 months, a process that normally takes a decade.

“The announcement today takes us another step closer to the time when we can use vaccines to bring an end to the devastation caused by [the virus],” said the vaccine’s architect Prof Sarah Gilbert.

What did the trial show?

More than 20,000 volunteers were involved, half in the UK, the rest in Brazil.

There were 30 cases of Covid in people who had two doses of the vaccine and 101 cases in people who received a dummy injection.

The researchers said it works out at 70% protection.

When volunteers were given two “high” doses the protection was 62%, but this rose to 90% when people were given a “low” dose followed by a high one. It’s not clear why there is a difference.

“We’re really pleased with these results,” Prof Andrew Pollard, the trial’s lead investigator, told the BBC.

He said the 90% effectiveness data was “intriguing” and would mean “we would have a lot more doses to distribute.”

There were also lower levels of asymptomatic infection in the low followed by high dose group which “means we might be able to halt the virus in its tracks,” Prof Pollard said.

BBC

You might also like